Researchers from the University of Illinois Urbana-Champaign report that in vivo CRISPR base editing reversed Huntington’s disease–associated toxic protein burden and neurological symptoms in mouse models. The approach does not aim to fully switch off the HTT gene; instead, it edits a splice acceptor region in exon 13 to reduce production of proteolysis-prone mutant fragments. The work is described as generating proteolysis-resistant HTT isoforms by disrupting splice acceptor sites linked to N-terminal fragment production. Leads on the strategy include Pablo Perez-Pinera, MD, PhD, and Thomas Gaj, PhD, both associate professors at UIUC. The paper positions base editing as a more surgical way to modulate pathogenic processing rather than eliminate the protein. With current clinical interest in multiple genome-editing modalities, the preclinical result strengthens the rationale for shifting toward editing designs that preserve broader HTT biology while reducing downstream toxic cleavage. Translational next steps will hinge on delivery, durability of splice changes, and off-target assessment.